GENENTECH, INC for GENENTECH INC
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Taxation/Internal Revenue Code TAX
Tax reform; general tax issues and tax extenders (R&D tax credit) and tax; Research and Development Tax credit; Specific issues lobbied (bill numbers): R&D Tax Credit issues; S. 3521, Family and Business Tax Cut Certainty Act of 2012; S. 1577 Greater Research Opportunities with Tax Help Act; H.R. 942, American Research and Competitiveness Act of 2011; H.R. 8
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Sr. Director |
| ELI KOGAN | Assistant Director |
Health Issues HCR
Issues relate to the 340B Drug discount program; Issues related to the implementation of the follow-on biologics provisions in P.L. 111-148 - "Patient Protection and Affordable Care Act;Legislation on public health preparedness and response related to pandemic influenza. Influenza Pandemic Preparedness federal, state and local levels. Legislation on screening, care and treatment for hepatitis.; Implementation of H.R. 1: Medicare Prescription Drug and Modernization Act of 2003; Issues relating to PDUFA stimulus. Avastin-use in breast cancer treatment: general patient reform issue: implementation of the Affordable Care Act of 2010; proposed cuts to Part B reimbursement. 340b reimbursement policy; Issues related to the implementation of the Affordable Care Act of 2010; Issues relating to the treatment of biologics in international health programs.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Director |
Medicare/Medicaid MMM
Public Law 11-148, the Patient Protection and Affordable Care Act - Implementation issues related to Medicare and Medicard reimbursement for biotherapeutics. Meetings with House and Senate staff on coverage/payment issues related to cancer biotherapeutics. P.L. 112-240, the American Taxpayer Relief Act of 2012 - Medicare payment issues.; Medicare coverage and payment of Part B drugs and biologicals; Monitor implementation of Medicare pharmaceutical coverage and reimbursement, 340B, dual elgible demonstrations and related provisions Part B; Medicare reimbursement for physicians of The Affordable Care Act; Proposed cuts to Part B reimbursement
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| EVAN MORRIS | Vice President of Government Affairs |
| KATHERINE RAAB | Director |
Budget/Appropriations BUD
Tax reform;Issues related to FDA & HHS program funding, FY13 Labor Health and Human Services, and Education, and Related Agencies Appropriations bill.;Following issues related to the budget and appropriations process FY 13 appropriations for FDA as well as the potential outcomes for negotiations on altering sequestration targets via legislation; FY13 Labor, HHS and Education Appropriation related to preparedness for pandemic influenza, HIV/AIDS programs, hepatitis screening, care and treatment, and access to breast cancer treatment; FY13 appropriations bills, including issues related to FDA funding and drug approval/review oversight process. FY13 sequestration process; Issues related to comprehensive tax reform, tax treatment of foreign-owned U.S. corporations, and tax extenders, including R&D tax credit. International trade issues and patent protection abroad; FY 14 appropriations process.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARIN GARDNER | Sr. Director |
| ELI KOGAN | Assistant Director |
| EVAN MORRIS | Vice President of Government Affairs |
Pharmacy PHA
Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicare prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010- Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription drug benefit. Public Law 112-144, the Food and Drug Administration Safety and Innovation Act - legislation related to re-authorization of user fees for prescription drug, medical device, and biologics approval. All aspects. General issues and congressional oversight related to FDA approval and CMS coverage decisions regarding Avastin and Lucentis.; proposed cuts to Part B reimbursement. 340b reimbursement policy; matters related to Tamiflu
| Lobbyist | Covered position, as disclosed |
|---|---|
| DAVID B BURT | Director |
| DARIN GARDNER | Sr. Director |
| KATHERINE RAAB | Director |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.